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heart failure (ADHF) from other syndroms. Our aim was to get insights
into the pathophysiological conditions leading to altered expression of
QSOX1 through the use of HF model rats.
Methods: Using thoracic aortic constriction (TAC), a model that rap-
idly progresses from cardiac hypertrophy to AHF as shown by echocardio-
graphic and anatomical data, we analyzed the level of QSOX1 transcript.
mRNA expression was measured by RT-qPCR and that of proteins by
Western-Blot.
Results: Qsox1 mRNAs were up-regulated (x4; p<0.05) in the LV of TAC
animals at 12 days post surgery, together with depressed LV shortening fraction.
BNP mRNAs show an earlier rise (x2.1; p<0.05), at 4.5 days post surgery.
QSOX1 mRNA level was also up-regulated in the left atria (x2.1; p<0.05), 56
days after surgery, the time when LA hypertrophy is maximum and AHF is truly
developed. Of note all other tissues, so far tested (liver, kidney, skeletal muscle,
lung), expressed similar QSOX1 level whatever groups and time after surgery.
Furthermore unaltered QSOX1 expression was noticed in chronic HF car-
diac tissues (with ejection fraction <30%) whereas BNP was elevated (x2.8;
p= 0.03). Thus data in human plasma that links QSOX1 to the AHF pathogen-
esis are corroborated in the animal models showing QSOX1 induction in both
the LV and the LA in AHF rats associated with severe pulmonary congestion.
Conclusion: Studies in rat models show that QSOX1 expression is induced
as a result of pressure overload leading to heart failure. We propose QSOX1
as new marker for aid in diagnosis of AHF patients.
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Beta-blocker use improves left ventricular ejection fraction (LVEF) in
patients with heart failure. A similar effect of beta-blockers on right ventric-
ular function has been proposed, although the effect of Bisoprolol on right
ventricular function has not been assessed.
This study investigated the short-term effect of Bisoprolol on right ventricular
function in chronic heart failure patients. A cohort of 60 heart failure patients who
were not taking beta-blockers at baseline was studied prospectively. Right ventric-
ular ejection fraction (RVEF) and LVEF were measured at both baseline and
6 months by echocardiography. Various parameters of the right ventricular func-
tion were measured: Simpson RVEF, surface shortening fraction, right ventricular
outflow tract (RVOT %), TAPSE (mm), S' wave with tissue doppler (S' dti cm/s),
and the Tei index. The threshold of significativity was fixed at 5%. Bisoprolol was
up titred during six months by a preestablished protocol to a target dose of 10 mg/
Od. Mean age was 65.7±16.3 years. Baseline RVEF was 25.6±5.2% and baseline
LVEF was 20.8±6.4%. Mean Bisoprolol dose reached was 25±12.5 mg daily. At
12 months, RVEF was significantly increased by 7.5% (95% confidence interval,
3.9-10.2; p=0.0001) and LVEF also increased significantly by 7.5% (95% confi-
dence interval, 4.0%-11.9%; p=0.0003). All the parameters of the right ventricular
function were significantly improved:
TAPSE (15.5 vs 12.7; p=0.078), Doppler S’dti cm/s (10.7 vs 8.2; p=0.002),
tei index (54.10vs 81.45; p=0.0008, RVOT% (27.1 vs 19.3; p=0.036), dp/dt
RV (721vs 505; p=0.05).
The efficacy and good tolerance of bisoprolol is demonstrated in this study
on chronic heart failure with right ventricular dysfunction when administered
in a precise pattern
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Purpose: Emergency extra-corporeal membrane oxygenation (ECMO)
implantation for severe cardiac shock or refractory cardiac arrest (under car-
diac massage), conducted in hospitals with on-site cardiac surgical facilities,
has been reported as both safe and effective. We report the feasibility, in-hos-
pital complications and outcomes of ECMO implantation, in a local hospital
without on-site cardiac surgical facilities.
Methods: This single-centre, prospective, consecutive cohort study
involved 50 pts who had ECMO implantation (2006-2010). Of these pts, 26
were in severe cardiac shock and 24 in refractory cardiac arrest. Implantations
were done by an interventional cardiologist team available 24/7, and in collab-
oration with the nearest cardiac surgical institution, located 100 km away, to
which patients were transferred subsequently.
Results: Stable ECMO implantation was achieved in 89% of pts in severe
cardiac shock and in 79% in refractory cardiac arrest. In-hospital complica-
tions occurred in 20/23 pts in cardiac shock and 13/23 were discharged alive.
In-hospital complications occurred in 18/19 pts in refractory cardiac arrest and
1/19 was discharged alive.
Conclusion: In a hospital with no cardiac surgical facilities, rates of
implantation failure, initial complications, and hospital outcomes in pts who
had ECMO implantation for severe cardiac shock or refractory cardiac arrest
were concordant with previous reports from hospitals with cardiac surgical
facilities. We observed a low rate of survival among implanted pts in refrac-
tory cardiac arrest.
Table – Outcomes for patients in severe cardiac shock or refractory cardiac 
arrest undergoing ECMO implantation
129
Peripheral chemoreflex activation contributes to sympathetic barore-
flex impairment in chronic heart failure
Angelicca Vaccaro [Orateur] (1), Fabien Despas (1), Marc Labrunee (1),
Marine Lebrin (1), Michel Galinier (2), Jean-Michel Senard (1), Atul
Pathak (1)
(1) Inserm U1048, Equipe 8, Toulouse, France – (2) CHU Toulouse, Car-
diologie, Toulouse, France
Chemoreflex-mediated sympathetic activation contributes to both initiation
and progression of chronic heart failure (CHF).
Aims: to study the direct role of increased peripheral chemosensitivity in
reducing sympathetic baroreflex function in CHF patients.
Methods and results: we compared sympathetic baroreflex function assessed
by the slope of the relationship between muscle sympathetic nerve activity
(MSNA) and diastolic blood pressure in CHF patients with augmented (n=18) and
normal (n=20) peripheral chemosensitivity. Using a double-blind, randomized,
vehicle-controlled study we examined the effect of chemoreflex deactivation (by
breathing 100% oxygen for 15 min) on sympathetic baroreflex function in CHF
patients with elevated and with normal chemosensitivity. Baseline MSNA was
elevated (60.6±3.2 versus 48.9±3.7 bursts/min; P<0.05) and sympathetic barore-
flex function impaired (3.06±0.55 vs 5.51±0.69 %bursts/mmHg, P<0.05) in CHF
patients with augmented peripheral chemosensitivity compared with controls.
Administration of 100% oxygen led to a significant decrease in MSNA (from
60.5±3.2 to 52.6±3.2 bursts/min; P<0.001) and increase in sympathetic baroreflex
(from 2.95±0.56 to 6.18±0.77; P<0.001) in CHF patients with enhanced chemore-
flex sensitivity. In contrast, neither room air nor 100% oxygen changed MSNA,
hemodynamics or sympathetic baroreflex function in CHF patients with normal
chemosensitivity.
Conclusion: we report for the first time that increased peripheral chemore-
flex sensitivity directly decrease sympathetic baroreflex function in CHF
patients. This interaction contributes to sympathetic overactivity and blunted
sympathetic baroreflex function of CHF patients and may explain how
chemoreceptors contribute to the bad prognosis of CHF patients.
Outcome Severe cardiac 
shock 
(n=26) 
Refractory cardiac 
arrest 
(n=24) 
Stable EMCO implantation achieved (%) 23 (89) 19 (79) 
Median duration of external cardiac 
massage, min (IQR)
– 90 (43-57) 
In-hospital complications (%) 20/23 (87) 18/19 (95) 
In-hospital death 10/23 (44) 18/19 (95)
